New 'Cicada' COVID Variant BA.3.2 Detected in UK, Health Officials Monitor Spread
Health officials in the United Kingdom are closely monitoring the emergence of a new COVID-19 variant, designated BA.3.2 and nicknamed the "cicada" strain. This variant is likely circulating at low levels within the UK after being identified in international travelers arriving from multiple continents.
Global Spread and Detection
The BA.3.2 variant was initially detected in South Africa in November 2024. According to the Centers for Disease Control and Prevention (CDC), it has now been identified in at least 23 countries worldwide. Cases linked to international travel have included discoveries among individuals returning to the United States from various nations, including the UK.
Researchers classify BA.3.2 as a "highly divergent" new lineage of COVID-19, genetically distinct from the predominant JN.1 variants of recent years. Similar to earlier strains, it contains mutations in the virus's spike protein, which is responsible for entering human cells. These mutations may affect how easily the variant transmits and how effectively it can evade immune defenses.
Timeline of Emergence
Following its initial detection in a respiratory specimen from a young child in South Africa, the variant appeared sporadically in early 2025. Confirmed cases were reported in Mozambique by March 2025 and in European countries such as the Netherlands and Germany by April 2025.
However, worldwide detections did not begin to increase notably until September 2025. The peak number of reported cases occurred in early December 2025, marking a significant moment in its transmission trajectory.
Between November 2025 and January 2026, BA.3.2 accounted for approximately 30% of sequenced COVID-19 cases in nations including Denmark, Germany, and the Netherlands. Despite this rise, public health authorities observed that overall infection numbers did not exceed normal seasonal trends.
Current Situation in the UK
While confirmed case figures in the UK remain small, the variant's identification among international travelers and its presence across Europe suggest it is probably already spreading at low levels within the country. Specialists warn that deficiencies in global genomic surveillance may mean the actual scale of BA.3.2's transmission is being underestimated.
Symptoms and Health Guidance
Symptoms associated with BA.3.2 appear largely consistent with other strains of COVID-19. They can vary between individuals and may improve with rest, fluids, and over-the-counter medications. The variant can also cause asymptomatic infections, meaning some people may not experience illness but can still transmit the virus.
The National Health Service (NHS) lists potential symptoms of COVID-19, which include:
- A high temperature or shivering (chills)
- A new, continuous cough
- A loss or change to sense of smell or taste
- Shortness of breath
- Feeling tired or exhausted
- An aching body
- A headache
- A sore throat
- A blocked or runny nose
- Loss of appetite
- Diarrhea
- Feeling sick or being sick
Concerns About Immune Evasion
Initial analysis suggests the cicada variant may be better able to evade antibodies produced through previous infection or vaccination, raising concerns about diminished immune protection. The CDC has emphasized that continued monitoring is crucial, particularly to evaluate vaccine effectiveness and determine whether updated formulations may be necessary.
Public Health Impact and Response
While the critical stage of the pandemic has subsided, COVID-19 still presents a significant health risk. During the 2024–25 respiratory virus season, the CDC estimates there were between 390,000 and 550,000 hospitalizations and up to 64,000 deaths associated with the virus.
Authorities caution that BA.3.2 could contribute to future seasonal surges in infections, highlighting the necessity for ongoing surveillance and swift response strategies. UK health bodies have not announced any immediate changes to public health advice but state they are collaborating with international counterparts to monitor the variant and assess its potential impact.
